Halozyme Therapeutics (HALO) Stock Forecast, Price Target & Predictions
HALO Stock Forecast
Halozyme Therapeutics stock forecast is as follows: an average price target of $56.86 (represents a -3.97% downside from HALO’s last price of $59.21) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.
HALO Price Target
The average price target for Halozyme Therapeutics (HALO) is $56.86 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $65.00 to $44.00. This represents a potential -3.97% downside from HALO's last price of $59.21.
HALO Analyst Ratings
According to 8 Wall Street analysts, Halozyme Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for HALO stock is 0 'Strong Buy' (0.00%), 7 'Buy' (87.50%), 1 'Hold' (12.50%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Halozyme Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 07, 2024 | Mitchell Kapoor | H.C. Wainwright | $65.00 | $51.44 | 26.36% | 9.78% |
| Jun 07, 2024 | Joseph Catanzaro | Piper Sandler | $51.00 | $51.44 | -0.86% | -13.87% |
| Jun 07, 2024 | Mohit Bansal | Wells Fargo | $58.00 | $51.44 | 12.75% | -2.04% |
| Jun 06, 2024 | Corinne Jenkins | Goldman Sachs | $44.00 | $51.44 | -14.46% | -25.69% |
| Jan 11, 2023 | - | Leerink Partners | $61.00 | $55.70 | 9.52% | 3.02% |
| Dec 21, 2022 | - | Morgan Stanley | $65.00 | $58.63 | 10.86% | 9.78% |
| Nov 28, 2022 | - | Wells Fargo | $65.00 | $55.53 | 17.04% | 9.78% |
| Nov 22, 2022 | - | J.P. Morgan | $54.00 | $52.74 | 2.39% | -8.80% |
The latest Halozyme Therapeutics stock forecast, released on Jun 07, 2024 by Mitchell Kapoor from H.C. Wainwright, set a price target of $65.00, which represents a 26.36% increase from the stock price at the time of the forecast ($51.44), and a 9.78% increase from HALO last price ($59.21).
Halozyme Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 3 | 4 |
| Avg Price Target | - | $58.00 | $54.50 |
| Last Closing Price | $59.21 | $59.21 | $59.21 |
| Upside/Downside | -100.00% | -2.04% | -7.95% |
In the current month, the average price target of Halozyme Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Halozyme Therapeutics's last price of $59.21. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 07, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Aug 07, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
| Jul 16, 2024 | Wells Fargo | Market Outperform | Market Outperform | Hold |
| Jul 16, 2024 | Piper Sandler | Underperform | Underperform | Hold |
| Jun 25, 2024 | Benchmark | Buy | Buy | Hold |
| Jun 24, 2024 | Piper Sandler | Underperform | Underperform | Hold |
| Jun 24, 2024 | Wells Fargo | Market Outperform | Market Outperform | Hold |
| Jun 07, 2024 | Wells Fargo | Overweight | Overweight | Hold |
| Jun 07, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 06, 2024 | Piper Sandler | Overweight | Neutral | Downgrade |
Halozyme Therapeutics's last stock rating was published by Cowen & Co. on Aug 07, 2024. The company gave HALO a "Buy" rating, the same as its previous rate.
Halozyme Therapeutics Financial Forecast
Halozyme Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $216.03M | $221.04M | $162.14M | $181.50M | $208.98M | $152.37M | $117.28M | $102.00M | $115.83M | $136.46M | $89.02M | $121.70M | $65.32M | $55.22M | $25.35M | $53.66M | $46.23M | $39.15M | $56.95M | $30.87M | $29.57M |
| Avg Forecast | $301.37M | $292.49M | $279.97M | $261.20M | $307.19M | $259.47M | $204.94M | $199.74M | $231.00M | $216.08M | $199.95M | $179.26M | $192.05M | $191.17M | $138.63M | $128.25M | $101.54M | $105.84M | $104.12M | $84.88M | $120.01M | $59.90M | $66.68M | $42.96M | $56.93M | $54.96M | $42.76M | $67.83M | $35.78M | $28.46M |
| High Forecast | $323.59M | $314.05M | $300.61M | $280.46M | $329.83M | $277.45M | $220.05M | $214.47M | $237.20M | $235.13M | $214.69M | $192.48M | $206.21M | $205.27M | $148.82M | $137.68M | $109.00M | $113.62M | $111.77M | $91.12M | $128.83M | $64.30M | $71.58M | $46.12M | $61.12M | $59.00M | $45.91M | $72.81M | $42.93M | $34.15M |
| Low Forecast | $289.76M | $281.22M | $269.18M | $251.13M | $295.35M | $252.14M | $197.05M | $192.04M | $227.81M | $198.56M | $192.24M | $172.35M | $184.65M | $183.80M | $134.00M | $123.97M | $98.15M | $102.31M | $100.64M | $82.04M | $116.00M | $57.90M | $64.45M | $41.53M | $55.03M | $53.12M | $41.34M | $65.56M | $28.62M | $22.77M |
| # Analysts | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 3 | 6 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 11 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.00% | 1.11% | 0.90% | 0.95% | 1.09% | 1.10% | 0.91% | 1.00% | 1.09% | 1.31% | 1.05% | 1.01% | 1.09% | 0.83% | 0.59% | 0.94% | 0.84% | 0.92% | 0.84% | 0.86% | 1.04% |
Halozyme Therapeutics's average Quarter revenue forecast for Dec 23 based on 6 analysts is $231.00M, with a low forecast of $227.81M, and a high forecast of $237.20M. HALO's average Quarter revenue forecast represents a 6.93% increase compared to the company's last Quarter revenue of $216.03M (Sep 23).
Halozyme Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 3 | 6 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 11 |
| EBITDA | - | - | - | - | - | - | - | - | - | $88.28M | $115.09M | $71.64M | $79.06M | $112.50M | $46.61M | $76.45M | $57.64M | $76.61M | $94.00M | $30.79M | $79.08M | $42.06M | $31.70M | $113.00K | $-29.69M | $-21.92M | $-10.96M | $6.01M | $-21.48M | $-26.64M |
| Avg Forecast | $108.29M | $105.09M | $100.60M | $93.85M | $110.37M | $93.23M | $73.64M | $96.90M | $83.00M | $77.64M | $71.84M | $88.10M | $69.01M | $53.22M | $49.81M | $80.09M | $36.48M | $38.03M | $37.41M | $38.97M | $43.12M | $21.52M | $23.96M | $124.30K | $20.46M | $19.75M | $15.37M | $6.01M | $-24.41M | $-25.57M |
| High Forecast | $116.27M | $112.84M | $108.01M | $100.77M | $118.51M | $99.69M | $79.07M | $116.29M | $85.23M | $84.48M | $77.14M | $105.71M | $74.09M | $63.87M | $53.47M | $96.10M | $39.17M | $40.83M | $40.16M | $46.76M | $46.29M | $23.11M | $25.72M | $149.16K | $21.96M | $21.20M | $16.49M | $7.22M | $-19.53M | $-20.46M |
| Low Forecast | $104.11M | $101.04M | $96.72M | $90.23M | $106.12M | $90.60M | $70.80M | $77.52M | $81.85M | $71.35M | $69.08M | $70.48M | $66.35M | $42.58M | $48.15M | $64.07M | $35.27M | $36.76M | $36.16M | $31.17M | $41.68M | $20.80M | $23.16M | $99.44K | $19.77M | $19.09M | $14.85M | $4.81M | $-29.29M | $-30.69M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.14% | 1.60% | 0.81% | 1.15% | 2.11% | 0.94% | 0.95% | 1.58% | 2.01% | 2.51% | 0.79% | 1.83% | 1.95% | 1.32% | 0.91% | -1.45% | -1.11% | -0.71% | 1.00% | 0.88% | 1.04% |
6 analysts predict HALO's average Quarter EBITDA for Dec 23 to be $83.00M, with a high of $85.23M and a low of $81.85M. This is -5.98% lower than Halozyme Therapeutics's previous annual EBITDA (Sep 23) of $88.28M.
Halozyme Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 3 | 6 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 11 |
| Net Income | - | - | - | - | - | - | - | - | - | $81.84M | $74.75M | $39.62M | $57.70M | $61.63M | $22.68M | $60.11M | $66.77M | $216.59M | $91.46M | $27.89M | $73.16M | $36.21M | $25.82M | $-6.10M | $-34.40M | $-25.02M | $-14.62M | $1.80M | $-27.46M | $-32.90M |
| Avg Forecast | $171.87M | $161.53M | $151.19M | $139.56M | $166.05M | $129.71M | $95.46M | $75.70M | $106.61M | $91.25M | $81.41M | $68.82M | $38.61M | $150.47M | $60.73M | $62.56M | $49.71M | $54.72M | $56.20M | $35.30M | $68.32M | $25.16M | $31.82M | $-6.71M | $-23.54M | $-15.69M | $-18.24M | $1.80M | $-31.21M | $-31.58M |
| High Forecast | $188.34M | $177.01M | $165.68M | $152.94M | $181.97M | $136.19M | $104.61M | $90.84M | $110.51M | $97.50M | $89.21M | $82.58M | $42.30M | $180.57M | $66.54M | $75.07M | $54.46M | $59.95M | $61.57M | $42.37M | $74.85M | $27.57M | $34.86M | $-5.37M | $-22.51M | $-15.01M | $-17.45M | $2.16M | $-24.96M | $-25.26M |
| Low Forecast | $163.25M | $153.43M | $143.61M | $132.57M | $157.73M | $123.22M | $90.68M | $60.56M | $102.71M | $82.50M | $77.33M | $55.05M | $36.67M | $120.38M | $58.10M | $50.05M | $47.55M | $52.35M | $53.76M | $28.24M | $65.35M | $24.07M | $30.44M | $-8.06M | $-25.78M | $-17.19M | $-19.99M | $1.44M | $-37.45M | $-37.90M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.90% | 0.92% | 0.58% | 1.49% | 0.41% | 0.37% | 0.96% | 1.34% | 3.96% | 1.63% | 0.79% | 1.07% | 1.44% | 0.81% | 0.91% | 1.46% | 1.59% | 0.80% | 1.00% | 0.88% | 1.04% |
Halozyme Therapeutics's average Quarter net income forecast for Dec 23 is $106.61M, with a range of $102.71M to $110.51M. HALO's average Quarter net income forecast represents a 30.27% increase compared to the company's last Quarter net income of $81.84M (Sep 23).
Halozyme Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 3 | 6 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 11 |
| SG&A | - | - | - | - | - | - | - | - | - | $35.27M | $38.95M | $37.36M | $37.75M | $34.47M | $57.48M | $13.83M | $13.77M | $13.17M | $12.32M | $11.06M | $10.43M | $11.70M | $10.97M | $12.63M | $23.93M | $17.98M | $17.34M | $18.01M | $13.56M | $12.62M |
| Avg Forecast | $64.85M | $62.94M | $60.25M | $56.21M | $66.10M | $55.83M | $44.10M | $17.42M | $49.71M | $46.50M | $43.03M | $15.84M | $41.33M | $9.15M | $29.83M | $14.40M | $21.85M | $22.78M | $22.40M | $14.00M | $25.82M | $12.89M | $14.35M | $13.90M | $12.25M | $11.83M | $9.20M | $18.01M | $15.40M | $12.11M |
| High Forecast | $69.63M | $67.58M | $64.69M | $60.35M | $70.97M | $59.70M | $47.35M | $20.91M | $51.04M | $50.60M | $46.20M | $19.01M | $44.37M | $10.98M | $32.02M | $17.28M | $23.46M | $24.45M | $24.05M | $16.80M | $27.72M | $13.84M | $15.40M | $16.67M | $13.15M | $12.70M | $9.88M | $21.61M | $18.49M | $14.53M |
| Low Forecast | $62.35M | $60.51M | $57.92M | $54.04M | $63.55M | $54.26M | $42.40M | $13.94M | $49.02M | $42.73M | $41.37M | $12.67M | $39.73M | $7.32M | $28.83M | $11.52M | $21.12M | $22.02M | $21.66M | $11.20M | $24.96M | $12.46M | $13.87M | $11.12M | $11.84M | $11.43M | $8.89M | $14.40M | $12.32M | $9.69M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.76% | 0.91% | 2.36% | 0.91% | 3.77% | 1.93% | 0.96% | 0.63% | 0.58% | 0.55% | 0.79% | 0.40% | 0.91% | 0.76% | 0.91% | 1.95% | 1.52% | 1.88% | 1.00% | 0.88% | 1.04% |
Halozyme Therapeutics's average Quarter SG&A projection for Dec 23 is $49.71M, based on 6 Wall Street analysts, with a range of $49.02M to $51.04M. The forecast indicates a 40.94% rise compared to HALO last annual SG&A of $35.27M (Sep 23).
Halozyme Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 3 | 6 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 11 |
| EPS | - | - | - | - | - | - | - | - | - | $0.62 | $0.57 | $0.29 | $0.43 | $0.45 | $0.16 | $0.44 | $0.48 | $1.53 | $0.64 | $0.20 | $0.54 | $0.27 | $0.19 | $-0.04 | $-0.24 | $-0.17 | $-0.10 | $0.01 | $-0.19 | $-0.26 |
| Avg Forecast | $1.33 | $1.25 | $1.17 | $1.08 | $1.28 | $1.00 | $0.74 | $0.69 | $0.82 | $0.71 | $0.63 | $0.38 | $0.30 | $0.36 | $0.47 | $0.46 | $0.38 | $0.42 | $0.43 | $0.32 | $0.53 | $0.19 | $0.25 | $-0.02 | $-0.18 | $-0.12 | $-0.14 | $0.01 | $-0.25 | $-0.24 |
| High Forecast | $1.46 | $1.37 | $1.28 | $1.18 | $1.41 | $1.05 | $0.81 | $0.75 | $0.86 | $0.75 | $0.69 | $0.42 | $0.33 | $0.40 | $0.51 | $0.51 | $0.42 | $0.46 | $0.48 | $0.35 | $0.58 | $0.21 | $0.27 | $-0.02 | $-0.17 | $-0.12 | $-0.14 | $0.02 | $-0.20 | $-0.19 |
| Low Forecast | $1.26 | $1.19 | $1.11 | $1.03 | $1.22 | $0.95 | $0.70 | $0.65 | $0.79 | $0.64 | $0.60 | $0.36 | $0.28 | $0.34 | $0.45 | $0.44 | $0.37 | $0.41 | $0.42 | $0.30 | $0.51 | $0.19 | $0.24 | $-0.02 | $-0.20 | $-0.13 | $-0.15 | $0.01 | $-0.30 | $-0.29 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.88% | 0.90% | 0.76% | 1.44% | 1.24% | 0.34% | 0.95% | 1.25% | 3.61% | 1.47% | 0.63% | 1.02% | 1.39% | 0.77% | 1.93% | 1.32% | 1.40% | 0.71% | 0.72% | 0.76% | 1.08% |
According to 6 Wall Street analysts, Halozyme Therapeutics's projected average Quarter EPS for Dec 23 is $0.82, with a low estimate of $0.79 and a high estimate of $0.86. This represents a 33.06% increase compared to HALO previous annual EPS of $0.62 (Sep 23).
Halozyme Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| EWTX | Edgewise Therapeutics | $17.52 | $48.00 | 173.97% | Buy |
| VRDN | Viridian Therapeutics | $14.09 | $36.36 | 158.06% | Buy |
| RARE | Ultragenyx Pharmaceutical | $55.24 | $108.14 | 95.76% | Buy |
| APLS | Apellis Pharmaceuticals | $41.05 | $75.81 | 84.68% | Buy |
| LRMR | Larimar Therapeutics | $8.05 | $14.50 | 80.12% | Buy |
| LEGN | Legend Biotech | $48.29 | $78.78 | 63.14% | Buy |
| CYTK | Cytokinetics | $54.09 | $80.92 | 49.60% | Buy |
| ASND | Ascendis Pharma | $119.15 | $175.15 | 47.00% | Buy |
| BMRN | BioMarin Pharmaceutical | $84.08 | $111.41 | 32.50% | Buy |
| BGNE | BeiGene | $191.32 | $247.75 | 29.50% | Buy |
| DICE | DICE Therapeutics | $47.55 | $60.00 | 26.18% | Buy |
| BPMC | Blueprint Medicines | $86.43 | $101.50 | 17.44% | Buy |
| EXEL | Exelixis | $25.15 | $28.00 | 11.33% | Buy |
| AGIO | Agios Pharmaceuticals | $43.28 | $47.33 | 9.36% | Buy |
| INSM | Insmed | $71.04 | $76.25 | 7.33% | Buy |
| ALNY | Alnylam Pharmaceuticals | $246.78 | $250.16 | 1.37% | Buy |
| HALO | Halozyme Therapeutics | $59.21 | $56.86 | -3.97% | Buy |
| PTGX | Protagonist Therapeutics | $41.50 | $38.00 | -8.43% | Buy |
| CERE | Cerevel Therapeutics | $44.96 | $33.50 | -25.49% | Buy |
HALO Forecast FAQ
Is Halozyme Therapeutics a good buy?
Yes, according to 8 Wall Street analysts, Halozyme Therapeutics (HALO) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 7 'Buy' recommendations, accounting for 87.50% of HALO's total ratings.
What is HALO's price target?
Halozyme Therapeutics (HALO) average price target is $56.86 with a range of $44 to $65, implying a -3.97% from its last price of $59.21. The data is based on 8 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Halozyme Therapeutics stock go up soon?
According to Wall Street analysts' prediction for HALO stock, the company can go down by -3.97% (from the last price of $59.21 to the average price target of $56.86), up by 9.78% based on the highest stock price target, and down by -25.69% based on the lowest stock price target.
Can Halozyme Therapeutics stock reach $90?
HALO's average twelve months analyst stock price target of $56.86 does not support the claim that Halozyme Therapeutics can reach $90 in the near future.
What are Halozyme Therapeutics's analysts' financial forecasts?
Halozyme Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $971.34M (high $1.04B, low $936.57M), average EBITDA is $374.15M (high $413.55M, low $345.04M), average net income is $466.92M (high $513.61M, low $432.19M), average SG&A $183.46M (high $198.94M, low $174.15M), and average EPS is $3.71 (high $4.02, low $3.53). HALO's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $1.14B (high $1.22B, low $1.09B), average EBITDA is $407.83M (high $437.89M, low $392.11M), average net income is $624.14M (high $683.96M, low $592.87M), average SG&A $244.24M (high $262.25M, low $234.83M), and average EPS is $4.83 (high $5.29, low $4.59).
Did the HALO's actual financial results beat the analysts' financial forecasts?
Based on Halozyme Therapeutics's last annual report (Dec 2022), the company's revenue was $660.12M, beating the average analysts forecast of $650.11M by 1.54%. Apple's EBITDA was $310.68M, beating the average prediction of $252.13M by 23.22%. The company's net income was $202.13M, missing the average estimation of $312.37M by -35.29%. Apple's SG&A was $143.53M, beating the average forecast of $94.7M by 51.55%. Lastly, the company's EPS was $1.48, missing the average prediction of $1.59 by -7.02%. In terms of the last quarterly report (Sep 2023), Halozyme Therapeutics's revenue was $216.03M, missing the average analysts' forecast of $216.08M by -0.02%. The company's EBITDA was $88.28M, beating the average prediction of $77.64M by 13.70%. Halozyme Therapeutics's net income was $81.84M, missing the average estimation of $91.25M by -10.32%. The company's SG&A was $35.27M, missing the average forecast of $46.5M by -24.15%. Lastly, the company's EPS was $0.62, missing the average prediction of $0.706 by -12.20%